Dyslipidemia
Conditions
Keywords
Hepatic Insufficiency
Brief summary
This study will evaluate the Area Under the Curve (AUC(0 to infinity)) of anacetrapib.
Interventions
DRUGanacetrapib
single dose administration of anacetrapib (MK0859) 100 mg oral tablet
Sponsors
Merck Sharp & Dohme LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Female subjects of reproductive potential test negative for pregnancy and agree to use two acceptable methods of birth control throughout the study * Subject is in good health * Subject agrees to refrain from consumption of red wine, grapefruit, orange and apple juices throughout the study
Exclusion criteria
* Patient has a history of cancer * Patient is a nursing mother * Patient is unable to refrain from or anticipates the use of any prescription or non-prescription medication during the study * Patient consumes excessive amounts of alcohol or caffeine * Patient has had major surgery, donated blood or participated in another investigational study within the past 4 weeks
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area Under the Curve (AUC(0 to infinity)) of anacetrapib | through 168 hours post dose |
Secondary
| Measure | Time frame |
|---|---|
| Tolerability of a single dose administration of 100mg anacetrapib, measured by the number of clinical and laboratory adverse events | through 14 days post dose |
Outcome results
None listed